Cargando…

Subtractionless compressed-sensing-accelerated whole-body MR angiography using two-point Dixon fat suppression with single-pass half-reduced contrast dose: feasibility study and initial experience

PURPOSE: To investigate the feasibility and clinical utility of a compressed-sensing-accelerated subtractionless whole-body MRA (CS-WBMRA) protocol with only contrast injection for suspected arterial diseases, by comparison to conventional dual-pass subtraction-based whole-body MRA (conventional-WBM...

Descripción completa

Detalles Bibliográficos
Autores principales: Fu, Qing, Lei, Zi-qiao, Li, Jing-yang, Wu, Jia-wei, Liu, Xiao-ming, Fan, Wen-liang, Sun, Peng, Wang, Jia-zheng, Liu, Ding-xi, Yang, Fan, Zheng, Chuan-sheng, Kong, Xiang-chuang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10360239/
https://www.ncbi.nlm.nih.gov/pubmed/37475047
http://dx.doi.org/10.1186/s12968-023-00953-w
_version_ 1785076059608186880
author Fu, Qing
Lei, Zi-qiao
Li, Jing-yang
Wu, Jia-wei
Liu, Xiao-ming
Fan, Wen-liang
Sun, Peng
Wang, Jia-zheng
Liu, Ding-xi
Yang, Fan
Zheng, Chuan-sheng
Kong, Xiang-chuang
author_facet Fu, Qing
Lei, Zi-qiao
Li, Jing-yang
Wu, Jia-wei
Liu, Xiao-ming
Fan, Wen-liang
Sun, Peng
Wang, Jia-zheng
Liu, Ding-xi
Yang, Fan
Zheng, Chuan-sheng
Kong, Xiang-chuang
author_sort Fu, Qing
collection PubMed
description PURPOSE: To investigate the feasibility and clinical utility of a compressed-sensing-accelerated subtractionless whole-body MRA (CS-WBMRA) protocol with only contrast injection for suspected arterial diseases, by comparison to conventional dual-pass subtraction-based whole-body MRA (conventional-WBMRA) and available computed tomography angiography (CTA). MATERIALS AND METHODS: This prospective study assessed 86 patients (mean age, 56 years ± 16.4 [standard deviation]; 25 women) with suspected arterial diseases from May 2021 to December 2022, who underwent CS-WBMRA (n = 48, mean age, 55.9 years ± 16.4 [standard deviation]; 25 women) and conventional-WBMRA (n = 38, mean age, 48 years ± 17.4 [standard deviation]; 20 women) on a 3.0 T MRI after random group assignment based on the chronological order of enrolment. Of all enrolled patients administered the CS-WBMRA protocol, 35% (17/48) underwent CTA as required by clinical demands. Two experienced radiologists independently scored the qualitative image quality and venous enhancement contamination. Quantitative image assessment was carried out by determining and comparing the apparent signal-to-noise ratios (SNRs) and contrast-to-noise ratios (CNRs) of four representative arterial segments. The total examination time and contrast-dose were also recorded. The independent samples t-test or the Wilcoxon rank sum test was used for statistical analysis. RESULTS: The overall scores of CS-WBMRA outperformed those of conventional-WMBRA (3.40 ± 0.60 vs 3.22 ± 0.55, P < 0.001). In total, 1776 and 1406 arterial segments in the CS-WBMRA and conventional-WBMRA group were evaluated. Qualitative image scores for 7 (of 15) vessel segments in the CS-WMBRA group had statistically significantly increased values compared to those of the conventional-WBMRA groups (P < 0.05). Scores from the other 8 segments showed similar image quality (P > 0.05) between the two protocols. In the quantitative analysis, overall apparent SNRs were significantly higher in the conventional-WBMRA group than in the CS-WBMRA group (214.98 ± 136.05 vs 164.90 ± 118.05; P < 0.001), while overall apparent CNRs were not significantly different in these two groups (CS vs conventional: 107.13 ± 72.323 vs 161.24 ± 118.64; P > 0.05). In the CS-WBMRA group, 7 of 1776 (0.4%) vessel segments were contaminated severely by venous enhancement, while in the convention-WBMRA group, 317 of 1406 (23%) were rated as severe contamination. In the CS-WBMRA group, total examination and reconstruction times were only 7 min and 10 min, respectively, vs 20 min and < 30 s for the conventional WBMRA group, respectively. The contrast agent dose used in the CS-WBMRA protocol was reduced by half compared to conventional-WBMRA protocol (18.7 ± 3.5 ml vs 37.2 ± 5.4 ml, P = 0.008). CONCLUSION: The CS-WBMRA protocol provides excellent image quality and sufficient diagnostic accuracy for whole-body arterial disease, with relatively faster workflow and half-dose reduction of contrast agent, which has greater potential in clinical practice compared with conventional-WBMRA.
format Online
Article
Text
id pubmed-10360239
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-103602392023-07-22 Subtractionless compressed-sensing-accelerated whole-body MR angiography using two-point Dixon fat suppression with single-pass half-reduced contrast dose: feasibility study and initial experience Fu, Qing Lei, Zi-qiao Li, Jing-yang Wu, Jia-wei Liu, Xiao-ming Fan, Wen-liang Sun, Peng Wang, Jia-zheng Liu, Ding-xi Yang, Fan Zheng, Chuan-sheng Kong, Xiang-chuang J Cardiovasc Magn Reson Research PURPOSE: To investigate the feasibility and clinical utility of a compressed-sensing-accelerated subtractionless whole-body MRA (CS-WBMRA) protocol with only contrast injection for suspected arterial diseases, by comparison to conventional dual-pass subtraction-based whole-body MRA (conventional-WBMRA) and available computed tomography angiography (CTA). MATERIALS AND METHODS: This prospective study assessed 86 patients (mean age, 56 years ± 16.4 [standard deviation]; 25 women) with suspected arterial diseases from May 2021 to December 2022, who underwent CS-WBMRA (n = 48, mean age, 55.9 years ± 16.4 [standard deviation]; 25 women) and conventional-WBMRA (n = 38, mean age, 48 years ± 17.4 [standard deviation]; 20 women) on a 3.0 T MRI after random group assignment based on the chronological order of enrolment. Of all enrolled patients administered the CS-WBMRA protocol, 35% (17/48) underwent CTA as required by clinical demands. Two experienced radiologists independently scored the qualitative image quality and venous enhancement contamination. Quantitative image assessment was carried out by determining and comparing the apparent signal-to-noise ratios (SNRs) and contrast-to-noise ratios (CNRs) of four representative arterial segments. The total examination time and contrast-dose were also recorded. The independent samples t-test or the Wilcoxon rank sum test was used for statistical analysis. RESULTS: The overall scores of CS-WBMRA outperformed those of conventional-WMBRA (3.40 ± 0.60 vs 3.22 ± 0.55, P < 0.001). In total, 1776 and 1406 arterial segments in the CS-WBMRA and conventional-WBMRA group were evaluated. Qualitative image scores for 7 (of 15) vessel segments in the CS-WMBRA group had statistically significantly increased values compared to those of the conventional-WBMRA groups (P < 0.05). Scores from the other 8 segments showed similar image quality (P > 0.05) between the two protocols. In the quantitative analysis, overall apparent SNRs were significantly higher in the conventional-WBMRA group than in the CS-WBMRA group (214.98 ± 136.05 vs 164.90 ± 118.05; P < 0.001), while overall apparent CNRs were not significantly different in these two groups (CS vs conventional: 107.13 ± 72.323 vs 161.24 ± 118.64; P > 0.05). In the CS-WBMRA group, 7 of 1776 (0.4%) vessel segments were contaminated severely by venous enhancement, while in the convention-WBMRA group, 317 of 1406 (23%) were rated as severe contamination. In the CS-WBMRA group, total examination and reconstruction times were only 7 min and 10 min, respectively, vs 20 min and < 30 s for the conventional WBMRA group, respectively. The contrast agent dose used in the CS-WBMRA protocol was reduced by half compared to conventional-WBMRA protocol (18.7 ± 3.5 ml vs 37.2 ± 5.4 ml, P = 0.008). CONCLUSION: The CS-WBMRA protocol provides excellent image quality and sufficient diagnostic accuracy for whole-body arterial disease, with relatively faster workflow and half-dose reduction of contrast agent, which has greater potential in clinical practice compared with conventional-WBMRA. BioMed Central 2023-07-20 /pmc/articles/PMC10360239/ /pubmed/37475047 http://dx.doi.org/10.1186/s12968-023-00953-w Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Fu, Qing
Lei, Zi-qiao
Li, Jing-yang
Wu, Jia-wei
Liu, Xiao-ming
Fan, Wen-liang
Sun, Peng
Wang, Jia-zheng
Liu, Ding-xi
Yang, Fan
Zheng, Chuan-sheng
Kong, Xiang-chuang
Subtractionless compressed-sensing-accelerated whole-body MR angiography using two-point Dixon fat suppression with single-pass half-reduced contrast dose: feasibility study and initial experience
title Subtractionless compressed-sensing-accelerated whole-body MR angiography using two-point Dixon fat suppression with single-pass half-reduced contrast dose: feasibility study and initial experience
title_full Subtractionless compressed-sensing-accelerated whole-body MR angiography using two-point Dixon fat suppression with single-pass half-reduced contrast dose: feasibility study and initial experience
title_fullStr Subtractionless compressed-sensing-accelerated whole-body MR angiography using two-point Dixon fat suppression with single-pass half-reduced contrast dose: feasibility study and initial experience
title_full_unstemmed Subtractionless compressed-sensing-accelerated whole-body MR angiography using two-point Dixon fat suppression with single-pass half-reduced contrast dose: feasibility study and initial experience
title_short Subtractionless compressed-sensing-accelerated whole-body MR angiography using two-point Dixon fat suppression with single-pass half-reduced contrast dose: feasibility study and initial experience
title_sort subtractionless compressed-sensing-accelerated whole-body mr angiography using two-point dixon fat suppression with single-pass half-reduced contrast dose: feasibility study and initial experience
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10360239/
https://www.ncbi.nlm.nih.gov/pubmed/37475047
http://dx.doi.org/10.1186/s12968-023-00953-w
work_keys_str_mv AT fuqing subtractionlesscompressedsensingacceleratedwholebodymrangiographyusingtwopointdixonfatsuppressionwithsinglepasshalfreducedcontrastdosefeasibilitystudyandinitialexperience
AT leiziqiao subtractionlesscompressedsensingacceleratedwholebodymrangiographyusingtwopointdixonfatsuppressionwithsinglepasshalfreducedcontrastdosefeasibilitystudyandinitialexperience
AT lijingyang subtractionlesscompressedsensingacceleratedwholebodymrangiographyusingtwopointdixonfatsuppressionwithsinglepasshalfreducedcontrastdosefeasibilitystudyandinitialexperience
AT wujiawei subtractionlesscompressedsensingacceleratedwholebodymrangiographyusingtwopointdixonfatsuppressionwithsinglepasshalfreducedcontrastdosefeasibilitystudyandinitialexperience
AT liuxiaoming subtractionlesscompressedsensingacceleratedwholebodymrangiographyusingtwopointdixonfatsuppressionwithsinglepasshalfreducedcontrastdosefeasibilitystudyandinitialexperience
AT fanwenliang subtractionlesscompressedsensingacceleratedwholebodymrangiographyusingtwopointdixonfatsuppressionwithsinglepasshalfreducedcontrastdosefeasibilitystudyandinitialexperience
AT sunpeng subtractionlesscompressedsensingacceleratedwholebodymrangiographyusingtwopointdixonfatsuppressionwithsinglepasshalfreducedcontrastdosefeasibilitystudyandinitialexperience
AT wangjiazheng subtractionlesscompressedsensingacceleratedwholebodymrangiographyusingtwopointdixonfatsuppressionwithsinglepasshalfreducedcontrastdosefeasibilitystudyandinitialexperience
AT liudingxi subtractionlesscompressedsensingacceleratedwholebodymrangiographyusingtwopointdixonfatsuppressionwithsinglepasshalfreducedcontrastdosefeasibilitystudyandinitialexperience
AT yangfan subtractionlesscompressedsensingacceleratedwholebodymrangiographyusingtwopointdixonfatsuppressionwithsinglepasshalfreducedcontrastdosefeasibilitystudyandinitialexperience
AT zhengchuansheng subtractionlesscompressedsensingacceleratedwholebodymrangiographyusingtwopointdixonfatsuppressionwithsinglepasshalfreducedcontrastdosefeasibilitystudyandinitialexperience
AT kongxiangchuang subtractionlesscompressedsensingacceleratedwholebodymrangiographyusingtwopointdixonfatsuppressionwithsinglepasshalfreducedcontrastdosefeasibilitystudyandinitialexperience